Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Cancer & Oncology — Weekly Report — November 2, 2026

Home/Health Insights/Cancer & Oncology — November 2 – November 9, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Cancer & Oncology
Updated Monday · November 16, 2026
Cancer & Oncology · November 2 – November 9, 2026

Cancer & Oncology
Weekly Report

This week's data 197 new clinical trials registered across 10 countries, with 18,822 trials actively recruiting patients worldwide.
Week of November 2 – November 9, 2026
  • 197 new clinical trials registered across 10 countries.
  • 18,822 trials actively recruiting patients worldwide.
  • Notable trial: MACE and BTK Inhibitors (10000 patients).
  • 3,297 new research papers published.
  • Top cited: "Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck ..." (JCO global oncology, 1 citations).
  • Drug safety: Most reported effect across tracked medications (pembrolizumab, nivolumab, trastuzumab, rituximab, paclitaxel) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · November 2 – November 9, 2026
New Trials This Week
197.
registered Nov 2–Nov 9
Recruiting Now
18,822
active trials seeking patients
Countries
10
with active trials this week
Papers Published
3,297
new studies this week
Phase 3 Trials
1
late-stage trials this week
Fig. 01

Trials by country

Count · November 2 – November 9, 2026
China
45
France
21
United States
14
Not specified
11
Italy
10
Norway
4
South Korea
3
Turkey (Türkiye)
2
Switzerland
1
Slovenia
1
0 12 24 36 45
total
Fig. 02

Trials by phase

Distribution · November 2 – November 9, 2026

New clinical trials registered this week for Cancer & Oncology. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

197 trials registered for Cancer & Oncology. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle Cancer & Oncology · University of Zurich (NCT07916779) Other Not Yet Recruiting 48 Switzerland
02 Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery Cancer & Oncology · Sir Run Run Shaw Hospital (NCT07920094) Other Recruiting 422 China
03 A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer Cancer & Oncology · Fudan University (NCT07920731) Phase 2 Enrolling By Invitation 45 China
04 Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial Cancer & Oncology · Oslo University Hospital (NCT07922967) Other Recruiting 60 Norway
05 Intravenously Administered PROMITIL Combined With Radiotherapy in Patients With Cisplatin-Ineligible Head and Neck Cancer Patients Cancer & Oncology · Assuta Ashdod Hospital (NCT07920289) Phase 2 Not Yet Recruiting 20 N/A
06 Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer Cancer & Oncology · Anhui Provincial Hospital (NCT07920159) Phase 2 Not Yet Recruiting 76 N/A
07 Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial Cancer & Oncology · Assistance Publique - Hôpitaux de Paris (NCT07915037) Phase 3 Not Yet Recruiting 254 France
08 Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC Cancer & Oncology · Fujian Medical University Union Hospital (NCT07917429) Other Not Yet Recruiting 610 China
09 Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity Cancer & Oncology · Karadeniz Technical University (NCT07921290) Other Not Yet Recruiting 64 N/A
10 POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions Cancer & Oncology · SimonMed Imaging (NCT07916311) Other Not Yet Recruiting 130 United States
11 Blood Brain Barrier Dysfunction in Glioma and Epileptogenesis Cancer & Oncology · University College, London (NCT07909460) Other Not Yet Recruiting 56 N/A
12 Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer Cancer & Oncology · Tianjin Medical University Cancer Institute and Hospital (NCT07909863) Phase 2 Not Yet Recruiting 25 China
13 A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging Cancer & Oncology · Hexin (Suzhou) Pharmaceutical Technology Co., Ltd (NCT07920835) Phase 2 Recruiting 60 China
14 Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study Cancer & Oncology · The First Hospital of Jilin University (NCT07908888) Phase 4 Recruiting 26 China
15 Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Cancer & Oncology · St. Jude Children's Research Hospital (NCT07916389) Phase 2 Not Yet Recruiting 50 United States
16 Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema Cancer & Oncology · Halic University (NCT07919093) Other Enrolling By Invitation 44 Turkey (Türkiye)
17 Lived Experiences of Women Diagnosed With HPV Infection Cancer & Oncology · Bilecik Seyh Edebali Universitesi (NCT07920666) Other Recruiting 15 Turkey (Türkiye)
18 Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer Cancer & Oncology · Fujian Medical University Union Hospital (NCT07920770) Other Recruiting 100 China
19 Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer Cancer & Oncology · Peking Union Medical College Hospital (NCT07919431) Other Enrolling By Invitation 100 China
20 Peer Ambassador in Gyn Onc Trials Cancer & Oncology · Abramson Cancer Center at Penn Medicine (NCT07915336) Other Enrolling By Invitation 125 United States
21 Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer Cancer & Oncology · Fox Chase Cancer Center (NCT07908979) Phase 2 Recruiting 70 United States
22 Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cancer & Oncology · Jiangsu Simcere Pharmaceutical Co., Ltd. (NCT07912268) Phase 1 Not Yet Recruiting 270 China
23 Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response Cancer & Oncology · UNC Lineberger Comprehensive Cancer Center (NCT07916376) Other Not Yet Recruiting 12 United States
24 A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors Cancer & Oncology · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (NCT07911579) Phase 2 Not Yet Recruiting 154 China
25 Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery Cancer & Oncology · University Medical Centre Ljubljana (NCT07922759) Phase 4 Recruiting 20 Slovenia
26 Improved Facial Skin Quality and Quality of Life After VYC-12L Treatment in Breast Cancer Survivors Cancer & Oncology · Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia (NCT07917117) Other Recruiting 50 Spain
27 Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer Cancer & Oncology · National Health Research Institutes, Taiwan (NCT07908550) Phase 2 Not Yet Recruiting 55 Taiwan
28 Efficacy and Safety of Oral Ivermectin for Genital Warts Cancer & Oncology · University of Health Sciences Lahore (NCT07913321) Other Not Yet Recruiting 90 Pakistan
29 NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC Cancer & Oncology · Shanghai Zhongshan Hospital (NCT07919717) Phase 2 Not Yet Recruiting 35 China
30 Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma Cancer & Oncology · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (NCT07917949) Phase 2 Recruiting 34 China
31 FES PET/MRI for Occult Disease in Lobular Breast Cancer Cancer & Oncology · University of Wisconsin, Madison (NCT07910474) Phase 4 Not Yet Recruiting 30 United States
32 Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer Cancer & Oncology · Sun Yat-sen University (NCT07922928) Phase 2 Not Yet Recruiting 36 N/A
33 Alberta Cancer Exercise Dose in Colorectal Cancer Cancer & Oncology · University of Calgary (NCT07913906) Phase 2 Not Yet Recruiting 90 Canada
34 PET/CT-Guided Maintenance Therapy in Previously Untreated MZL Cancer & Oncology · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (NCT07917650) Phase 2 Active Not Recruiting 45 China
35 Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node Mapping in Patients With Endometrial Cancer Cancer & Oncology · Barretos Cancer Hospital (NCT07916610) Other Not Yet Recruiting 200 N/A
36 Intraoperative Visualization of Large Head and Neck Tumors to Optimize Radiation Therapy Planning Using Liquid Soft-tissue Markers Such as BioXmark® (During Definitive Treatment or in the Postoperative Setting) Cancer & Oncology · University Hospital, Essen (NCT07910799) Other Not Yet Recruiting 295 N/A
37 Arginine-Restricted Diet Combined With Chemoradiotherapy in Neoadjuvant Rectal Cancer: A Phase Ib/II Trial Cancer & Oncology · Xuelei Ma MD (NCT07912346) Phase 2 Not Yet Recruiting 126 N/A
38 MACE and BTK Inhibitors Cancer & Oncology · University Hospital, Caen (NCT07923162) Phase 4 Not Yet Recruiting 10,000 France
39 GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis Cancer & Oncology · Ruijin Hospital (NCT07923396) Phase 1 Not Yet Recruiting 10 China
40 Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer Cancer & Oncology · Washington University School of Medicine (NCT07914309) Phase 2 Not Yet Recruiting 17 United States
41 The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study Cancer & Oncology · Women's Hospital School Of Medicine Zhejiang University (NCT07916909) Other Recruiting 1,500 China
42 SERS-Based Diagnosis of Leptomeningeal Metastasis in EGFR-Mutant NSCLC Cancer & Oncology · limeifang (NCT07912723) Other Active Not Recruiting 74 China
43 New Italian Mastocytosis Registry Cancer & Oncology · Associazione Rete Italiana Mastocitosi (NCT07917156) Other Recruiting 1,500 Italy
44 Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids Cancer & Oncology · University of Novi Sad (NCT07923253) Other Active Not Recruiting 50 Serbia
45 Gut-Liver-Muscle Axis in Cancer Cachexia Cancer & Oncology · University of Colorado, Denver (NCT07911150) Other Not Yet Recruiting 20 United States
46 A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma Cancer & Oncology · MedSIR (NCT07917481) Phase 2 Not Yet Recruiting 44 N/A
47 Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA Cancer & Oncology · Eun Hye Lee (NCT07921888) Other Recruiting 40 South Korea
48 A Study of the Safety and Effectiveness of a Compound Steep-Pulse Therapy Apparatus for Malignant Liver Tumors Cancer & Oncology · REMD Medical Technology (NCT07916350) Other Completed 181 China
49 A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung Cancer Cancer & Oncology · Tang-Du Hospital (NCT07917767) Phase 2 Not Yet Recruiting 90 N/A
50 Phase Ib/II Trial of Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer Cancer & Oncology · Xuelei Ma MD (NCT07912463) Phase 2 Not Yet Recruiting 126 N/A
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Cancer & Oncology. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
nivolumab Off Label Use 820
trastuzumab Myelosuppression 707
rituximab Off Label Use 5,218
paclitaxel Myelosuppression 1,062

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Cancer & Oncology. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

3,297 papers

Recently published peer-reviewed studies related to Cancer & Oncology, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Distance and interruption: The violence of deportation among families enduring childhood cancer in the United States. Wright AG et al. 10.1111/maq.70103
View abstract

In recent years, the xenophobic rhetoric that has long shaped debates about immigration in the United States has reached a fever pitch, which has only helped enable structurally violent policies of mass deportation. This paper demonstrates the harmful impact of such policies on child cancer patients and their family members by drawing on collaborative, multimodal methods that bring online news coverage into conversation with ethnographic fieldwork at a safety-net children's hospital in California. Our analysis shows how these policies target undocumented and mixed-status families, making them structurally vulnerable to parent-child separation and familial removal, which can lead to life-threatening treatment delays and other traumas. By continuing to produce critical analyses of state violence and by bringing this work into conversation with pro-immigrant activism, medical anthropologists can help contribute to the abolition of institutions that enact anti-immigrant violence.

Medical anthropology quarterly 2026 Nov 8 PubMed
02 The Transformation of Oncology Drug Development in China: Toward a New Phase of Innovation. Chen Y et al. 10.1158/2159-8290.CD-26-1628
View abstract

UNLABELLED: China's oncology drug development ecosystem has shifted from rapid pipeline expansion toward clinical value-driven innovation. We review regulatory reform and the 2015 to 2025 evolution of clinical development across small molecules, mAbs, multispecific antibodies, antibody-drug conjugates, and cell and gene therapies. China's disease burden and enrollment capacity have enabled globally relevant advances in EGFR-mutant lung cancer, gastrointestinal malignancies, hepatocellular carcinoma, nasopharyngeal carcinoma, and CLDN18.2-directed therapies. We highlight persistent challenges in target and modality convergence, biomarker definition, therapeutic window optimization, manufacturing consistency, and globally interpretable evidence generation and discuss how artificial intelligence may connect target discovery, drug design, and clinical trial optimization more efficiently. SIGNIFICANCE: China has become a major source of oncology trials and modality innovation, but scale alone will not ensure global impact. This review links regulatory reform, disease-specific opportunity, target biology, therapeutic format, and evidence quality across a decade of solid tumor development. It defines the conditions under which China-originated programs can generate globally practice-changing evidence. See related article by Shi, p. XX .

Cancer discovery 2026 Nov 8 PubMed
03 The Landscape of National Natural Science Foundation of China-Sponsored Oncology Research Funding, 2016-2025. Shi R 10.1158/2159-8290.CD-26-2095
View abstract

Over the past decade, oncology has consistently ranked among the top in National Natural Science Foundation of China (NSFC) grant applications and funded projects across all research fields. Chinese researchers' preferences across cancer types and the evolutionary trends of oncology research areas point to key challenges and future potential funding trends in China.

Cancer discovery 2026 Nov 8 PubMed
04 Amyloid nomenclature 2026: update, novel proteins, and discussion of intracellular aggregates and toxicity. Recommendations by the International Society of Amyloidosis Nomenclature Committee. Buxbaum JN et al. 10.1080/13506129.2026.2754262
View abstract

Protein misfolding followed by aggregation into amyloid fibrils is a more common process than previously believed, and knowledge of the underlying mechanisms and their associations with disease is rapidly expanding. The International Society of Amyloidosis (ISA) has long maintained a Nomenclature Committee to meet the need for uniform terminology, amyloid protein names and abbreviations, and to harmonize these with other nomenclature systems. For this update, virtual meetings and electronic correspondence preceded the 2026 ISA meeting in Montevideo, Uruguay, resulting in the present revised document. Amyloid is defined by the beta-sheet structure of its principal fibril protein, although amyloid deposits formed contain additional components. The principles underlying the recommended amyloid nomenclature remain unchanged but have been further clarified. The number of known human amyloid fibril proteins associated with systemic amyloidosis remains 19. Most are linked to genetic variants and are extremely rare. In animals, nine different fibril proteins have been identified in association with systemic amyloidoses. The rapidly growing body of knowledge concerning pathological intracellular protein aggregates and their contribution to tissue vulnerability is covered in an expanded section of this paper.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026 Nov 8 PubMed
05 Investigating Factors Influencing the Long-Term Outcome of Teriparatide Treatment on the Risk of Hip Fracture. Is sequential treatment essential? Meszaros S et al. 10.1093/jbmr/zjag156
View abstract

INTRODUCTION: Teriparatide (TPTD) is an anabolic therapy for severe osteoporosis. Clinical trials have shown its efficacy in reducing vertebral and non-vertebral fractures, data on hip fracture prevention in real-world settings and the impact of sequential antiresorptive (AR) therapy remain limited. METHODS: We conducted a retrospective cohort study using the Hungarian National Health Insurance Database, which covers the entire population (~9.7 million). Patients with osteoporosis who received TPTD between 2010 and 2023, with treatment initiated by January 1, 2022. Hip fractures were tracked from day 180 after TPTD initiation for up to five years. Adherence was assessed via medication possession ratio. Post-TPTD AR therapy (bisphosphonate or denosumab) and the timing of its initiation were evaluated as factors influencing hip fracture risk. Poisson regression models were applied, adjusting for demographics, prior fractures, and healthcare utilization. RESULTS: Among 8,893 eligible patients, 574 hip fractures occurred during follow-up. High adherence was associated with reduced hip fracture risk by 20% (p<0.05). The number of fractures prior to treatment was also associated with fracture risk, increasing it by 11% (p<0.05). Delayed AR initiation was closely related to a proportional increase in risk, which grew proportionally with the time elapsed between the two treatments. In a cohort of patients exhibiting high adherence, deferring AR treatment for over 90 days post-TPTD therapy was associated with an increase of 19% in hip fracture risk when subsequent treatment involved bisphosphonates, and a 31% increase when denosumab was utilized as the follow-up therapy. CONCLUSIONS: The efficacy of teriparatide treatment was associated with patient adherence and the number of prior fractures. Neglecting to initiate AR treatment following teriparatide therapy, or starting it late, was strongly linked to an increased risk of hip fractures. Our findings provide real-world data supporting timely initiation of AR therapy post-TPTD for sustained fracture prevention.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2026 Nov 8 PubMed
06 Trends and Frontiers in Stem Cell Research for Sepsis: A Bibliometric Analysis (1990-2025). Han K et al. 10.2147/JIR.S578516
View abstract

PURPOSE: To systematically map the 35-year intellectual evolution of stem cell research in sepsis and identify emerging frontiers for clinical translation. METHODS: We retrieved 3890 publications (1990-2025) from the Web of Science Core Collection. Multi-dimensional bibliometric analyses, including co-citation networks, keyword bursts, and alluvial flow mapping, were performed using CiteSpace, HistCite, and R to delineate the field's trajectory. RESULTS: Annual publications increased significantly, peaking in 2024, with the USA and China as primary contributors. The research focus has undergone a major paradigm shift: from early "bone marrow transplantation" and hematopoietic reconstitution (1990s-2000s) to the immunomodulatory mechanisms of "mesenchymal stem cells" (2010s). Currently, the field has entered a "cell-free" era, characterized by intense research into "extracellular vesicles" and "exosomes" (2021-2025). Alluvial analysis identified "cancer", "immunotherapy", and "COVID-19" as dominant integrated modules. Notably, the emergence of "guidelines" and "precision care" highlights a growing emphasis on clinical standardization and targeted treatment for sepsis-induced organ failure. CONCLUSION: This study demonstrates that the frontier of sepsis therapy is moving toward refined, secretome-based biologics. Our findings provide a strategic roadmap for researchers to prioritize high-potential therapeutic targets and for clinicians to design more focused trials, ultimately accelerating the integration of stem cell-derived products into mainstream sepsis management.

Journal of inflammation research 2026 PubMed
07 Life Expectancy in Hairy Cell Leukemia: An Updated SEER Study of 5669 Patients. Mustafa A 10.2147/JBM.S637330
View abstract

INTRODUCTION: Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder affecting mature B-cells, predominantly observed in males. It is recognized by cytopenia, splenomegaly, myelofibrosis, and the presence of atypical lymphoid cells exhibiting distinctive cytoplasmic hairy projections. METHODS: This large updated population-based study utilized SEER database to evaluate 5669 hairy cell leukemia (HCL) patients diagnosed between 1978 and 2020. Univariate and multivariate Cox proportional hazards models were performed to identify key determinants of overall survival (OS). While the SEER database provides robust statistical power and broad generalizability, this analysis is inherently limited by registry-level constraints, including missing treatment details (such as specific chemotherapy regimens or lines of therapy), lack of relapse/progression data, and potential underreporting of comorbidities. RESULTS: Estimated median survival for HCL patients who aged less than 40 years was 39.3 (95% CI: 38.9-39.7 years) compared to 8.8 years (95% CI: 8.0-9.4 years) for HCL patients older than 65 years. CONCLUSION: This study demonstrates favorable long-term survival among patients with HCL. Improved OS is associated with more recent diagnosis (post-2006) and the use of advanced diagnostic methods. These findings suggest that long-term survival in HCL may approach that of the general population, though these findings reflect cohort-level observations without a matched population control.

Journal of blood medicine 2026 PubMed
08 Obstructive Jaundice in Sub-Saharan Africa: A Narrative Review of Diagnostic and Therapeutic Pathways, Contextual Challenges, and a Proposed Resource-Stratified Framework. Odulusi D et al. 10.2147/HMER.S649519
View abstract

Obstructive jaundice in sub-Saharan Africa (SSA) is managed in conditions that differ sharply from high-income practice. Regional case series report malignant causes, chiefly pancreatic head tumours and cholangiocarcinoma, as the leading aetiology, and endoscopic retrograde cholangiopancreatography (ERCP) remains scarce across most of the region. This narrative review synthesises the regional evidence, the contextual challenges that shape how it can be applied and the unresolved clinical practice gaps, and proposes a resource-stratified management framework. MEDLINE, African Journals Online, African Index Medicus and Google Scholar were searched from January 2000 to June 2026, giving priority to studies from, or directly addressing, SSA settings. The evidence is geographically incomplete and comes mainly from English-language, single-centre series in Uganda, Tanzania, Malawi, Ghana and Rwanda. Three observations emerge. First, reported aetiology and treatment may reflect locally available capacity as well as disease biology: the one Rwandan series with local ERCP and percutaneous drainage was stone-dominant and mostly treated without surgery, while series from centres without that capacity were malignancy-dominant and surgery-dominant. This is a hypothesis resting on one contrasting series, and differences in referral populations and case ascertainment may explain part of it. Second, delay accumulates along the care pathway, so low resectability at presentation partly reflects elapsed time. Third, outcome definitions differ between series, which prevents comparison. Three practice gaps follow: preoperative drainage guidance that assumes rapid access to surgery, little documented multidisciplinary input, and non-standardised outcome reporting. A six-part conceptual framework and a capacity-stratified algorithm are proposed, built from the authors' synthesis of this literature and clinical experience. Neither has been validated or piloted. Both need local adaptation, consensus testing and prospective evaluation before use as a clinical or reporting standard.

Hepatic medicine : evidence and research 2026 PubMed
09 Platelet-Tumor Interactions: From Mechanisms Promoting Metastasis to Novel Targeted Therapeutic Strategies. Liu W et al. 10.2147/IJN.S649895
View abstract

Platelets are anucleate blood cells that primarily mediate hemostasis and thrombosis. Tumor metastasis represents the leading cause of mortality among cancer patients, and platelet-mediated hematogenous metastasis constitutes a critical step facilitating the dissemination of tumor cells. A wealth of evidence has demonstrated a close correlation between platelets and tumor progression. Platelets aggregate around circulating tumor cells (CTCs) and drive tumor metastasis via multiple mechanisms: shielding CTCs from hemodynamic shear stress and immune cell attack, inducing epithelial-mesenchymal transition (EMT), promoting the formation of pre-metastatic niches (PMNs), and enabling immune evasion. Targeted therapeutic strategies built on the interplay between platelets and tumors are of great significance for restraining tumor metastasis and prolonging patient survival. This review comprehensively elaborates on the mechanisms by which platelets promote tumor metastasis, summarizes the merits and relevant strategies of platelet-targeted therapies, and offers novel insights for the suppression of tumor metastasis.

International journal of nanomedicine 2026 PubMed
10 Next-Generation Cancer Nanovaccines: Reprogramming the Tumor Microenvironment from Rational Design Toward Clinical Translation. Tabibzadeh S et al. 10.2147/IJN.S645776
View abstract

Cancer vaccines have emerged as a promising immunotherapeutic strategy for inducing durable and tumour-specific immune responses; however, their clinical efficacy remains limited by poor antigen immunogenicity, inefficient delivery, tumor heterogeneity, and the highly immunosuppressive tumor microenvironment (TME). Recent advances in nanotechnology have expanded opportunities for the rational engineering of multifunctional nanoparticle (NP) platforms that can protect therapeutic cargo, enhance antigen presentation and lymphatic transport, co-deliver immunostimulatory adjuvants, and potentially improve immune modulation while reducing systemic exposure. This narrative review provides an overview of next-generation cancer nanovaccines, including lipid-, polymer-, peptide-, inorganic-, biomimetic-, theranostic, in situ-, and stimuli-responsive platforms, with emphasis on their physicochemical design principles, mechanisms of immune activation, and interactions with the TME. Particular attention is given to strategies targeting tumor -associated macrophages, myeloid-derived suppressor cells, regulatory T cells, cancer-associated fibroblasts, and tumor cells to support dendritic-cell maturation, cytotoxic T-cell activation, and anti-tumor immunity. Emerging personalized approaches, including neoantigen- and autologous cell-based nanovaccines, mRNA vaccine platforms, and combinations with immune checkpoint inhibitors, are also discussed. In addition, we examine the growing role of artificial intelligence, machine learning, and computational immunology in neoantigen prioritization, nanoparticle formulation optimization, immunogenicity prediction, and patient-specific vaccine design. Despite encouraging preclinical findings, most cancer nanovaccine platforms remain at the preclinical or early clinical stage, and translation is limited by tumor heterogeneity, variable immune responses, long-term safety and biodistribution concerns, manufacturing reproducibility, scale-up, and regulatory requirements. Overall, the integration of nanotechnology, immunology, precision medicine, and AI offers considerable potential to advance personalized cancer vaccination, but broader clinical validation and standardized manufacturing and evaluation frameworks are required before these platforms can achieve routine clinical application.

International journal of nanomedicine 2026 PubMed
11 Stem Cell-Derived Extracellular Vesicles in Bladder Cancer: Diagnostic Potential and Therapeutic Challenges. Lu W et al. 10.2147/IJN.S631382
View abstract

With population aging, the high prevalence and recurrence rate of bladder cancer increasingly threaten the health of older adults. Although surgery is effective for most early-stage bladder cancer, frequent recurrence and the risk of metastasis compromise patients' quality of life, while subsequent radical surgery can cause a substantial further decline. Advances in nanobiomedicine have highlighted nanoscale vesicles as potential tools for the early diagnosis and treatment of bladder cancer, particularly as stem cell-based and stem cell-derived vesicle-based nanomedicine approaches mature. Studies suggest that extracellular vesicles derived from mesenchymal stem cells and bladder cancer stem cells, enriched in specific bioactive molecules and characterized by strong targeting capabilities and low immunogenicity, may support early diagnosis and cell-free targeted therapy for bladder cancer, potentially reducing its high recurrence rate and risk of metastasis. This review therefore summarizes preclinical studies of extracellular vesicles derived from malignant and nonmalignant stem cells in bladder cancer and discusses their diagnostic and therapeutic potential to expand nanomedicine approaches to bladder cancer diagnosis and treatment.

International journal of nanomedicine 2026 PubMed
12 Best Practice and Management of Sexual Dysfunction Following Diagnosis and Treatment of Gynecological Cancer. Sha S et al. 10.2147/IJWH.S583630
View abstract

Sexual dysfunction, defined as a clinically significant and persistent disturbance in sexual desire, arousal, orgasm, or pain during sexual activity, affects up to 90% of gynecologic cancer survivors. Sexual health is a well-established component of quality of life, and its assessment should be routinely integrated into survivorship care. Treatment with surgery, chemotherapy, and/or radiation can result in early menopause, disruption of pelvic vasculature and nerve innovation, and alteration of pelvic anatomy that profoundly impacts sexual health. These physical consequences from treatment can compound the psychological burden that accompanies a cancer diagnosis. Here we review the evidence and provide recommendations for the evaluation and management of sexual dysfunction following the diagnosis and treatment of gynecologic cancer. We will discuss the mechanisms by which cancer-directed therapies affect sexual health, multimodal symptom-based treatment approaches, and lastly highlights awareness for continued areas of advocacy with the goal of providing all patients with comprehensive survivorship care.

International journal of women's health 2026 PubMed
13 The Cathepsin Network: Multifaceted Regulators and Emerging Therapeutic Targets in Breast Cancer. Chen Y et al. 10.2147/BCTT.S635861
View abstract

Breast cancer metastasis remains the primary cause of mortality, driving the search for novel therapeutic vulnerabilities. The cathepsin family of lysosomal proteases has emerged as a pivotal signaling network that orchestrates tumor progression, therapy resistance, and organ-specific metastasis. This narrative review synthesizes current knowledge on key cathepsins (B, D, L, S, C, G, and V) in breast cancer, detailing their multifaceted roles in extracellular matrix remodeling, immune modulation, angiogenesis, and epigenetic regulation. We highlight their specialized functions: cathepsin B (CTSB) and cathepsin L (CTSL) as core executors of invasion; cathepsin S (CTSS), cathepsin C (CTSC), and cathepsin G (CTSG) as mediators of immune crosstalk and organotropic metastasis to brain, lung, and bone; and cathepsin D (CTSD)/cathepsin V (CTSV) as hormonally-linked regulators with nuclear roles. Critically, we evaluate the emerging preclinical strategies of cathepsins as diagnostic biomarkers and therapeutic targets, reviewing emerging strategies including small-molecule inhibitors, antibody-based therapies, activatable prodrugs, and imaging probes. Advancing the understanding of this context-dependent protease network and developing selective interventions hold significant promise for paving the way towards more effective and personalized treatment strategies.

Breast cancer (Dove Medical Press) 2026 PubMed
14 NIR-Sensitive Natural Attapulgite Nanoformulation for Effective Anti-Tumor Chemotherapeutic Activity in-vitro Model. Li D et al. 10.2147/IJN.S637061
View abstract

PURPOSE: Smart drug delivery systems enabling on-demand release and multimodal therapy are highly desirable for cancer treatment. Natural attapulgite (ATP) nanoclay possesses high surface area, good biocompatibility, and intrinsic near-infrared (NIR) absorption. This study aimed to develop an ATP-based nanoformulation incorporating gypenosides, inulin, folic acid, and lauric acid as a phase-change gatekeeper, and to evaluate its in vitro performance under NIR irradiation. METHODS: The formulation was prepared by spray-drying ATP with gypenosides, inulin, and folic acid, followed by lauric acid encapsulation. Characterization included morphology, pore structure, thermal properties, and photothermal conversion. In vitro drug release was assessed with or without 808 nm NIR irradiation. Cytotoxicity against HeLa cells was evaluated using the CCK-8 assay, comparing material alone, NIR alone, and material combined with NIR. RESULTS: The optimized microspheres (ATP-M) exhibited a hierarchical porous structure (surface area 27.0 m/g, average pore diameter 22.3 nm) and high lauric acid loading (~51 wt%). Lauric acid melted at ~43 °C, enabling NIR-triggered release. ATP-M showed efficient NIR absorption and photothermal heating. The combination of drug-loaded microspheres and NIR irradiation reduced HeLa cell viability to 24.9%, which was lower than chemotherapy alone (51.6%) or photothermal therapy alone (83.3%). CONCLUSION: The natural ATP-based nanoformulation enables NIR-triggered drug release and enhanced in vitro antitumor efficacy. These findings support further investigation of this system for potential cancer therapy, including in vivo validation of targeting and synergy.

International journal of nanomedicine 2026 PubMed
15 Multimodal AI in Oral Cancer: A PRISMA-Guided Systematic Review. Deka B et al. 10.1049/htl2.70105
View abstract

Oral cancer presents significant diagnostic and prognostic challenges, often due to late-stage detection and tumour heterogeneity. Recent advancements in artificial intelligence (AI), particularly deep learning (DL) and machine learning (ML), offer promising solutions by integrating multimodal biomedical data. This PRISMA-guided systematic review evaluates over 82 studies from 2015 to 2025 that apply convolutional neural networks, transformers and graph neural networks to oral cancer, using combinations of histopathology, radiology, genomics and clinical data. Results indicate that multimodal AI models consistently outperform unimodal approaches in diagnostic accuracy, AUC and survival prediction. Architectures employing attention mechanisms, graph embedding and fusion transformers demonstrate superior performance in tasks such as early lesion detection and treatment outcome modelling. Despite these advances, challenges persist in generalisability, data standardisation and clinical validation. Multimodal AI thus represents a paradigm shift toward precision oncology in oral cancer, warranting further research focused on interpretability, prospective validation and ethical clinical deployment.

Healthcare technology letters 2026 Jan-Dec PubMed
16 Molecular Profiling in Asia: The Current Status and Approach. Limaye S et al. 10.36401/JIPO-26-14
View abstract

Precision oncology has transformed cancer care globally through biomarker-driven and genomically guided treatment strategies. In Asia, where nearly 60% of the world's population resides, the implementation of molecular profiling presents both significant opportunities and unique challenges. Despite increasing adoption, precision diagnostics remain largely concentrated in urban and academic centers, with disparities in access, infrastructure, and expertise across the region. Advances in next-generation sequencing (NGS), including targeted gene panels, comprehensive genomic profiling, whole exome sequencing, and whole-genome sequencing, have enabled the identification of actionable alterations across multiple tumor types. Liquid biopsy approaches, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), are further transforming cancer care by enabling real-time disease monitoring and detection of resistance mechanisms. Integration of multiomics platforms is increasingly enhancing clinical decision-making. Molecular tumor boards play a critical role in interpreting complex genomic data and facilitating genomically guided treatment decisions, including targeted therapy selection, off-label treatment recommendations, and clinical trial enrollment. However, several barriers continue to limit widespread implementation of genetic testing in Asia, including high costs, limited reimbursement, inadequate infrastructure, lack of trained personnel, and insufficient genomic databases representing Asian populations. This review provides a comprehensive overview of current molecular diagnostic approaches, clinical applications, and evolving precision oncology practices in Asia. We also highlight key challenges and propose practical solutions, including physician and patient education, expansion of trial-matching platforms, and development of region-specific genomic datasets. Strengthening these areas will be essential for advancing equitable, accessible, and effective precision cancer care across Asia.

Journal of immunotherapy and precision oncology 2026 Nov PubMed
17 State of Precision Oncology: An Australian Perspective. Liaqat S et al. 10.36401/JIPO-25-29
View abstract

Precision oncology is redefining cancer therapeutics worldwide. In Australia, the integration of genomic medicine into routine clinical oncology remains inconsistently constrained by fragmented funding mechanisms, regional disparities, and a limited workforce. Understanding these structural and policy challenges is crucial for transitioning toward a sustainable, equitable genomic health ecosystem. This narrative review synthesizes evidence from national policy frameworks, peer-reviewed literature, and translational oncology initiatives to examine the current state of precision oncology in Australia. Key domains of analysis include clinical practice patterns, access and equity, infrastructure, data governance, regulatory oversight, and health-policy reform. Although major initiatives, such as Omico's Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) platform, the ZERO Childhood Cancer Program, and the forthcoming national coordination body Genomics Australia, demonstrate substantial progress, significant implementation barriers persist. Australia stands on the cusp of realizing a genomics-enabled model of cancer care. Consolidation of national governance under Genomics Australia, expansion of Medicare Benefits Schedule reimbursement for comprehensive genomic profiling, and integration of digital-innovation platforms will be pivotal to achieving an internationally replicable model for responsible, population-wide precision oncology.

Journal of immunotherapy and precision oncology 2026 Nov PubMed
18 Outcomes of Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors with and Without Lung and/or Liver Metastases (NCI/SWOG S1609). Wang Y et al. 10.36401/JIPO-26-29
View abstract

INTRODUCTION: Limited prior retrospective data, primarily among patients with lung cancer, liver cancer, and melanoma, has indicated that liver metastases are associated with poorer outcomes with chemotherapy, targeted agents, and checkpoint inhibitor therapy. We used a unique clinical trial resource to evaluate whether liver and/or lung metastases were associated with outcomes among patients with rare tumors treated with combination anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1 (programmed cell death protein 1) therapy. METHODS: The basket trial, SWOG trial S1609 (NCT02834013, DART trial), treated 655 eligible patients without lung or liver primary cancers. Associations with progression-free survival (PFS) and overall survival (OS) were evaluated with Cox regression models. Associations with clinical benefit rate (confirmed complete and partial response or stable disease for 6 months or longer) and treatment-related adverse events (per CTCAEv5) were evaluated using Fisher exact test. RESULTS: There was no significant difference in rates of grade 3 or higher treatment-related adverse events across the groups. Participants with liver metastases, with or without lung metastases, had a lower likelihood of experiencing clinical benefit (11% and 18%, respectively) compared with participants with lung but not liver metastases or participants with neither lung nor liver metastases (26% and 30%, respectively, = 0.003). On multivariable analysis, having both lung and liver metastases was associated with shorter PFS and OS compared with the presence of neither liver nor lung metastases when accounting for the number of RECIST (Response Evaluation Criteria in Solid Tumors) target sites. Compared with the presence of neither liver nor lung metastases, lung but not liver or liver but not lung sites of metastases were significantly associated with PFS but not OS in these multivariable models. CONCLUSIONS: In a diverse cohort of participants with advanced rare tumors treated with combination anti-CTLA-4 and anti-PD-1 therapy, we found that both the combination of lung and liver metastases was associated with shorter PFS and OS.

Journal of immunotherapy and precision oncology 2027 Feb PubMed
19 Molecular Profiling and Precision Oncology for Non-Small Cell Lung Cancer in Latin America: Unique Epidemiology, Persistent Barriers, and Paths Toward Equity. Picón CR et al. 10.36401/JIPO-26-16
View abstract

ABSTRACT: Non-small cell lung cancer (NSCLC) represents a critical public health crisis in Latin America (LA), the leading cause of cancer-associated mortality across the region. Although global incidence rates are shifting, the burden in low- and middle-income countries is projected to increase significantly by 2030. Beyond the impact of tobacco, LA faces unique challenges derived from environmental exposures and diverse genetic ancestry that shape a molecular landscape distinct from other regions. This has resulted in a high prevalence of actionable drivers, particularly mutations, positioning a large segment of the population as ideal candidates for precision medicine approaches. However, current efforts to address this epidemic fall short of regional needs, as the potential of precision oncology remains largely unrealized due to multilevel systemic and economic barriers. Despite the scientific potential of targeted therapies to drastically improve survival, LA has not broadly or expeditiously adopted these strategies. A profound implementation gap is characterized by a reliance on inefficient single-gene testing, fragmented regulatory frameworks, and severe infrastructural limitations. Consequently, only a minimal proportion of the regional patient population benefits from recent advances, whereas the majority continue to receive empirical chemotherapy with significantly inferior survival outcomes. Addressing these disparities requires a steadfast focus on systemic transformation, ranging from establishing centralized genomic hubs to implementing structured educational programs. Standardizing care through molecular tumor boards (MTBs) and harmonizing regulatory pathways are essential steps in translating research into clinical benefits. In this review, we discuss the unique molecular epidemiology of the region and the challenges of treatment implementation, focusing on the urgent need to integrate new technologies to ensure equitable access to precision oncology. LA has one of the highest potential population-level benefits from precision oncology in NSCLC; however, systemic barriers prevent this molecular opportunity from translating into equitable survival gains (Graphical abstract).

Journal of immunotherapy and precision oncology 2026 Nov PubMed
20 Combined Prognostic Value of Pre-Radiotherapy BMI and NRS-2002 for Overall Survival in Patients with Esophageal Cancer. Wu D et al. 10.2147/CMAR.S639380
View abstract

BACKGROUND & AIMS: Nutritional status significantly affects the treatment efficacy and survival outcomes of esophageal cancer patients receiving radiotherapy. Although body mass index (BMI) and Nutritional Risk Screening 2002 (NRS-2002) are well-established independent assessment tools, there is a lack of strong evidence validating their combinedprognostic value. This study aims to compare theprognostic value of the combined BMI and NRS-2002 model with that of single-indexmodels (BMI or NRS-2002) for survival in esophageal cancer patients undergoing radiotherapy. METHODS: A retrospective analysis was conducted on data from 676 esophageal cancer patients, with a median follow-up of 24 months. Cox regression analysis was used to evaluate the prognostic value of the combined model and single models, andthe Akaike Information Criterion (AIC) and C-index were used to compare model fit and discrimination. Meanwhile, the prognostic consistency of nutritional indicators was evaluated across key clinical subgroupssuch as TNM stage. RESULTS: Multivariate Cox regression analysis identified pre-radiotherapy BMI and NRS-2002 as independent prognostic factors for overall survival (OS). Compared to underweight patients, those with normal BMI (HR=0.599, 95% CI: 0.457-0.785, P<0.001) and overweight status (HR=0.689, 95% CI: 0.493-0.963, P=0.029) had significantly better survival. Conversely, nutritional risk (NRS-2002 ≥3) was associated with poorer survival (HR=1.279, 95% CI: 1.029-1.591, P=0.027). The combined model demonstrated superior model fit (lowest AIC: 5068.882) and discrimination (optimism-corrected C-index: 0.6597) compared to single-indicator models, although the incremental gain in discriminatory power was modest. CONCLUSION: Combining pre-radiotherapy BMI with the NRS-2002 provides a slight improvement in risk stratification for overall survival among esophageal cancer patients undergoing radiation therapy compared to a model based on a single indicator. Although this combined model offers complementary prognostic information, its incremental value in distinguishing patient risk is limited. In clinical practice, this combined assessment can serve as a practical adjunct to risk stratification, helping to identify high-risk patients who require comprehensive nutritional intervention. Further external validation in prospective cohorts is still needed.

Cancer management and research 2026 PubMed
21 Routine foreskin pathology in adults: Low yield, high cost-Time to change practice? McLean KA et al. 10.1002/bco2.70299
View abstract

OBJECTIVE: This study aimed to determine the diagnostic yield for malignant lesions and cost-effectiveness of routine foreskin pathology in adults. SUBJECTS/PATIENTS AND METHODS: A retrospective audit was conducted of all adult circumcisions (age ≥16) performed between January 2015 and February 2025 at a UK tertiary centre. Clinical and pathology records were reviewed to identify unexpected cancer diagnoses-defined as cases with no prior biopsy evidence or clinical suspicion. The number needed to screen (NNS) to detect one cancer was calculated, and pathology costs were estimated based on local processing costs and the pathologist workload score for each sample. RESULTS: There were 2503 adult circumcisions performed between 2015 and 2025, with 2.6% ( = 66/2503) cancers detected on pathological assessment. Of these, 78.8% ( = 52/66) patients with confirmed penile cancer had clinically suspicious findings pre-operatively. Therefore, the NNS on routine pathology for unexpected cancers was 109.4 (95% CI = 65.4-183.4), and only one clinically significant cancer (7.1%,  = 1/14 [0.04% overall cohort]) required further treatment (topical ablation). The diagnostic yield was also age-dependent, with low diagnostic yields in patients below age 40 with potentially suspicious pathology (NNS = 178.5, 95% CI: 49.5-650.3). Pathology-associated costs were estimated at £65 584 over the study period (£994 per cancer identified). Targeting pathology to men aged ≥40 with clinical suspicion of cancer would reduce costs by 73.3% (£48 074), while reducing the cost per cancer detected to £350. CONCLUSION: Routine foreskin pathology after adult circumcision has a low diagnostic yield for unexpected malignancy and rarely alters management. Targeting pathology to higher yield patient groups may optimise resource use, aligning with national guidelines and delivering substantial cost savings.

BJUI compass 2026 Nov PubMed
22 Clinically Suspected Tumefactive Demyelination Mimicking a Brain Tumor in a 10-Year-Old Boy: A Case Report. Aman F et al. 10.1002/ccr3.73887
View abstract

After cranial surgery, a 10-year-old boy developed hand weakness, numbness, and fatigue. MRI showed frontoparietal lesions; biopsy lacked documented demyelination. Symptoms and lesions reportedly improved after methylprednisolone. Tumefactive demyelination was suspected, but discordant laterality, unavailable antibody testing, and brief follow-up left the diagnosis unclassified.

Clinical case reports 2026 Nov PubMed
23 Fortuitous Discovery of Asymptomatic Homozygous Antithrombin Deficiency: A Rare p.Leu131Phe Heparin-Binding Site Mutation: A Case Report. Cherkaoui S et al. 10.1002/jha2.70398
View abstract

Homozygous Type II heparin-binding site antithrombin deficiency is a rare inherited thrombophilia associated with a high risk of early thrombotic events. We report a 6-week-old infant homozygous for the c.391C>T (p.Leu131Phe) variant (Antithrombin Budapest III), with markedly reduced antithrombin activity (12%). Despite this high-risk genotype, the patient remains asymptomatic without thrombotic or vascular abnormalities and has not required anticoagulant treatment to date. This case highlights the phenotypic heterogeneity of homozygous antithrombin Budapest III deficiency and the importance of genetic diagnosis, family screening, and careful long-term follow-up. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

EJHaem 2026 Dec PubMed
24 Neoadjuvant FOLFOXIRI in a Locally Advanced Right Colon Cancer Patient: A Case Report From a Limited-Resource Setting. Alazka O et al. 10.1155/crom/5532415
View abstract

BACKGROUND: Although upfront surgery followed by adjuvant chemotherapy is the standard of care for locally advanced colon cancer (LACC), high rates of recurrence and surgical morbidity remain significant challenges in bulky T4 tumors. Neoadjuvant chemotherapy (NAC) is gaining traction to improve downstaging and resectability. Although doublet regimens (FOLFOX/CAPOX) are established, the use of the intensive triplet regimen FOLFOXIRI in the neoadjuvant setting for nonmetastatic LACC is less common because of toxicity concerns and limited clinical data. CASE PRESENTATION: A 55-year-old male presented with a bulky, obstructive, right-sided colonic mass (cT4bN+M0). Given the high-risk features and the need for significant cytoreduction in a resource-limited setting where molecular profiling was unavailable, neoadjuvant FOLFOXIRI was initiated. After six cycles, the patient achieved an 85% reduction in tumor volume and normalization of tumor markers (CEA/CA19-9). Despite experiencing manageable Grade 3 neutropenia and anorexia, he underwent successful R0 resection. Histopathology confirmed significant downstaging to ypT2pN0 (0/12), reflecting a near-complete pathological response. Following four cycles of adjuvant CAPOX, the patient remains disease-free at 1.5 years. CONCLUSION: Neoadjuvant FOLFOXIRI can achieve significant downstaging in bulky tumors and facilitates R0 resection in selected high-risk LACC patients, even in resource-limited settings. Despite requiring careful management of treatment toxicities, triplet NAC offers exploratory, hypothesis-generating option for first colon cancer patients with T4 primary tumors, and can be further supported with future large clinical data.

Case reports in oncological medicine 2026 PubMed
25 Rare Sites of Metastases to the Breast and Integumentary System in Advanced Cervical Cancer at Initial Presentation in Eastern Uganda: A Case Report. Nteziyaremye JG et al. 10.2147/IMCRJ.S650965
View abstract

BACKGROUND: Cervical cancer (CC) is the leading Gynaecological cancer in Uganda with an estimated 6959 women diagnosed, and 4607 annual deaths. About 60-80% of CC patients present with advanced stage disease with either local spread or with distant metastases. For those with distant metastases, the most common sites of spread are the lungs and supraclavicular lymph nodes. Breast and integumentary system metastases are very rare. We present a case with such metastases managed in eastern Uganda. CASE PRESENTATION: A 72 years old, Ugandan black African female, came in with a 13 months history of intermittent postmenopausal bleeding and associated abnormal vaginal discharge. She had repeatedly been managed from the nearest health facility for recurrent urinary tract infection and sexually transmitted diseases with no improvement. On examination at Mbale Regional Referral Hospital, she had poor performance status, cachexic, with bilateral pitting, tender poedal oedema, left breast masses and cutaneous nodules on the anterior aspect of the left thigh. Abdominal exam revealed a bulky uterus. On vagina examination, a large easily bleeding cervical tumour measuring about 8 cm × 7 cm and involving the upper 1/3 of the vagina was found. Bimanual pelvic exam revealed bilateral parametria involvement and bilateral pelvic side wall extension. Biopsies of the cervical, breast and the cutaneous masses were positive for high grade adenocarcinoma. Immunohistochemistry (IHC) for breast and cutaneous biopsies was positive for 16-kilodalton protein (P16), and negative for Oestrogen receptors (ER) and Progesterone receptors (PR). A diagnosis of cervical adenocarcinoma stage IVB (with breast and integument system metastases), with obstructive uropathy and probable deep venous thrombosis was made. She was offered total palliation and unfortunately succumbed on day 3 of admission. CONCLUSION: Cervical adenocarcinoma stage IVB with breast and integumentary metastases portends poor prognosis. Gynaecologic Oncologists and other service providers need to do thorough exam and investigations to rule out metastases to rare sites. This will aid appropriate counselling during care.

International medical case reports journal 2026 PubMed
26 Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy Moushumi Suryavanshi et al. 10.1186/s12885-026-15894-7 BMC Cancer 2026 Scholar
27 Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS). A. Kapoor et al. 10.1200/GO-25-00721 1 citation JCO global oncology 2026 Scholar
28 Resection margin width as a risk factor for liver cancer recurrence M. Kamalova et al. 10.17816/onco703999 Russian Journal of Oncology 2026 Scholar
29 Abstract 1137: Validation of a sensitive, tissue-free blood test for biomarker discovery and tumor burden assessment Zeliang Deng et al. 10.1158/1538-7445.am2026-1137 Cancer Research 2026 Scholar
30 First-line pembrolizumab plus chemotherapy versus bevacizumab plus chemotherapy in response and survival outcomes in PD-L1-negative advanced non-squamous NSCLC: a retrospective comparative cohort study Kuo-Fang Huang et al. 10.21037/tlcr-2026-0917 Translational Lung Cancer Research 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Cancer & Oncology
  • Week: November 2 – November 9, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 11:16 PM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —